This Article Figures Only Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fenchel, S Articles by Merkle, E M Search for Related Content PubMed PubMed Citation Articles by Fenchel, S Articles by Merkle, E M

Effect of iodine concentration of contrast media on contrast enhancement in multislice CT of the pancreas

¹ Department of Radiology, University of Ulm, Steinhoevelstr. 9, 89075 Ulm, Germany, ² Department of Radiology, University Hospitals of Cleveland/Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA and ³ Bracco Altana Pharma GmbH, Max-Stromeyer- Str. 57, 78467 Konstanz, Germany

Correspondence: Sabine Fenchel, Department of Radiology, University of Ulm, Steinhövelstr. 9, D-89075 Ulm, Germany

The purpose of this study was to determine the influence of two different iodine concentrations of the non-ionic contrast agent, Iomeprol, on contrast enhancement in multislice CT (MSCT) of the pancreas. To achieve this MSCT of the pancreas was performed in 50 patients (mean age 57±14 years) with suspected or known pancreatic tumours. The patients were randomly assigned to group A (n=25 patients) or group B (n=25 patients). There were no statistically significant differences in age, height or weight between the patients of the two groups. The contrast agent, Iomeprol, was injected with iodine concentrations of 300 mg ml^–1 in group A (130 ml, injection rate 5 ml s^–1) and 400 mg ml^–1 in group B (98 ml, injection rate 5 ml s^–1). Arterial and portal venous phase contrast enhancement (HU) of the vessels, organs, and pancreatic masses were measured and a qualitative image assessment was performed by two independent readers. In the arterial phase, Iomeprol 400 led to a significantly greater enhancement in the aorta, superior mesenteric artery, coeliac trunk, pancreas, pancreatic carcinomas, kidneys, spleen and wall of the small intestine than Iomeprol 300. Portal venous phase enhancement was significantly greater in the pancreas, pancreatic carcinomas, wall of the small intestine and portal vein with Iomeprol 400. The two independent readers considered Iomeprol 400 superior over Iomeprol 300 concerning technical quality, contribution of the contrast agent to the diagnostic value, and evaluability of vessels in the arterial phase. No differences were found for tumour delineation and evaluability of infiltration of organs adjacent to the pancreas between the two iodine concentrations. In conclusion the higher iodine concentration leads to a higher arterial phase contrast enhancement of large and small arteries in MSCT of the pancreas and therefore improves the evaluability of vessels in the arterial phase.

This article has been cited by other articles:

				Y. Yanaga, K. Awai, Y. Nakayama, T. Nakaura, Y. Tamura, M. Hatemura, and Y. Yamashita Pancreas: Patient Body Weight tailored Contrast Material Injection Protocol versus Fixed Dose Protocol at Dynamic CT Radiology, November 1, 2007; 245(2): 475 - 482. [Abstract] [Full Text] [PDF]

				P. T. Johnson and E. K. Fishman IV Contrast Selection for MDCT: Current Thoughts and Practice Am. J. Roentgenol., February 1, 2006; 186(2): 406 - 415. [Abstract] [Full Text] [PDF]